Stockscreener 앱 받기
33.29
1.16%
-0.39
시간 외 거래:
32.70
-0.59
-1.77%
전일 마감가:
$33.68
열려 있는:
$33.3
하루 거래량:
6.43M
Relative Volume:
2.95
시가총액:
$9.51B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
117.51
EPS:
0.2833
순현금흐름:
$404.94M
1주 성능:
-4.97%
1개월 성능:
-3.92%
6개월 성능:
+53.20%
1년 성능:
+43.37%
1일 변동 폭
$33.11
$33.68
1주일 범위
$33.11
$36.22
52주 변동 폭
$19.20
$36.97
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
33.29 | 9.51B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
First Week of August 2025 Options Trading For Exelixis (EXEL) - Nasdaq
Exelixis downgraded to market perform by BMO Capital - MSN
The five-year decline in earnings might be taking its toll on Exelixis (NASDAQ:EXEL) shareholders as stock falls 4.3% over the past week - Simply Wall St
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by BMO Capital Markets - MarketBeat
Franklin Resources Inc. Has $20.85 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
Exelixis downgraded, price target raised to $40 on CRC drug outlook By Investing.com - Investing.com South Africa
Exelixis downgraded, price target raised to $40 on CRC drug outlook - Investing.com Canada
Zacks Research Has Bullish Estimate for Exelixis Q4 Earnings - MarketBeat
Peering Into Exelixis's Recent Short Interest - Benzinga
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cancer drug maker's stock faces ip hurdle - Investing.com
Barclays PLC Sells 102,720 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Y Intercept Hong Kong Ltd Lowers Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis downgraded on balanced risk/reward after stock surge By Investing.com - Investing.com South Africa
Exelixis cut to neutral from buy by BofA - MSN
Bank of America Downgrades Exelixis (NASDAQ:EXEL) to Neutral - MarketBeat
Exelixis (EXEL) Cancer Drug Partnership Hits $110M Milestone as ADU-1805 Advances in Clinical Trials - StockTitan
Exelixis downgraded on balanced risk/reward after stock surge - Investing.com
Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - Inkl
EXEL: Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies? - StockNews.com
Public Employees Retirement System of Ohio Has $2.95 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Sees Significant Increase in Short Interest - MarketBeat
Retirement Systems of Alabama Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
(EXEL) Investment Report - Stock Traders Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report - Benzinga
Tri Ri Asset Management Corp Buys New Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Kovitz Investment Group Partners LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges By Investing.com - Investing.com Canada
Exelixis's SWOT analysis: cabozantinib drives growth amid ip challenges - Investing.com
Unsupported price hikes added $815 million to US drug spending in 2023 - Marketscreener.com
State Street Corp Sells 1,157,988 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - MSN
Verition Fund Management LLC Invests $1.23 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - The Motley Fool
17,200 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Point72 DIFC Ltd - MarketBeat
Cerity Partners LLC Acquires 15,777 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Fmr LLC Has $63.89 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (LTS:0IJO) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Systematic Financial Management LP Has $30.32 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
NFJ Investment Group LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
18,635 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Paloma Partners Management Co - MarketBeat
Bank of Montreal Can Buys 35,496 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
BNP Paribas Financial Markets Sells 32,223 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis' (NASDAQ:EXEL) earnings growth rate lags the 29% CAGR delivered to shareholders - Yahoo Finance
Exelixis, Inc. (NASDAQ:EXEL) Stake Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
Erste Asset Management GmbH Purchases New Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Edgestream Partners L.P. - MarketBeat
Which GCs Sold Stock In November? Quest, Exelixis, More - Law360
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):